Ceftriaxone (CTRX), a parenteral cephalosporin antibiotic, was examined for its clinical utility in the treatment of purulent otitis media, and the following results were obtained. CTRX concentrations in the tissue membranes of the mastoid antrum were 15.73±8.83μg/g at 30 min. and 9.88±8.97μg/g at 60 minutes after intravenous injection with one gram of CTRX, while corresponding serum levels were 50.23±9.98μg/ml and 37.97±9.75μg/ml, indicating CTRX's good transfer into the tissues. Clinical efficacy was evaluated in 47 out of 50 cases that recieved CTRX; three cases were excluded, or dropped out. Of the 47 cases, 13 had acute otitis media, and 34 had chronic otitis media; 33 cases had a single infection, and 14 had mixed infections. In 38 cases, the drug was administered by intravenous injection, while 8 received CTRX by drip infusion. 29 cases received a one gram dose daily, and 15 received two grams once daily. The treatment period ranged from 3 to 11 days. Efficacy of CTRX was rated by the physician in charge at 72.3% in the 47 evaluated cases ; 76.7% if the 4 cases with
Pseudomonas infection were excluded. Efficacy was observed in 72.4% of the 29 cases that received a one gram once daily dose CTRX and 73.3% of the 15 cases that received 2g once daily. When cases with
Pseudomonas infection were excluded, the percentage of cases where efficacy was noted rose to 77.8% and 76.9%, respectively. When clinical efficacy was evaluated by the committee, efficacy was observed in 68.1% of the 47 evaluated cases, and in 72.1% of the 43 cases without
pseudomonas infections, indicating percentages of 4 to 5% lower than those evaluated by the physician in charge. The bacteriological efficacy of CTRX was also examined. The causative pathogen was eradicated in 78.8% of the 33 cases with a single pathogen, and in 76.9% of the 14 cases with mixed infections. When
pseudomonas infection cases were excluded, eradication was achieved in 80.6% and 90.9% respectively. The eradication rate for 22 strains of
Staphylococcus aureus was relatively low, only 66.7%, but it was satisfactory for other bacterial strains, except
Pseudomonas. Side effects were seen with CTRX. One case each of facial edema, erythema, and an edematous rash were seen, and laboratory findings revealed the ocurrence of leukopenia in two cases. It is considered from the above results that CTRX is highly clinically useful in once-a-day administrations of one or two grams, even for
Staphylococcal infections.
抄録全体を表示